Literature DB >> 17517880

Clostridium difficile toxins A and B directly stimulate human mast cells.

Gesa K A Meyer1, Anne Neetz, Gudrun Brandes, Dimitrios Tsikas, Joseph H Butterfield, Ingo Just, Ralf Gerhard.   

Abstract

Clostridium difficile toxins A and B (TcdA and TcdB) are the causative agents of antibiotic-associated pseudomembranous colitis. Mucosal mast cells play a crucial role in the inflammatory processes underlying this disease. We studied the direct effects of TcdA and TcdB on the human mast cell line HMC-1 with respect to degranulation, cytokine release, and the activation of proinflammatory signal pathways. TcdA and TcdB inactivate Rho GTPases, the master regulators of the actin cytoskeleton. The inactivation of Rho GTPases induced a reorganization of the actin cytoskeleton accompanied by morphological changes of cells. The TcdB-induced reorganization of the actin cytoskeleton in HMC-1 cells reduced the number of electron-dense mast cell-specific granules. Accordingly, TcdB induced the release of hexosaminidase, a marker for degranulation, in HMC-1 cells. The actin rearrangement was found to be responsible for degranulation since latrunculin B induced a comparable hexosaminidase release. In addition, TcdB as well as latrunculin B induced the activation of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase 1/2 and also resulted in a p38 MAPK-dependent increased formation of prostaglandins D(2) and E(2). The autocrine stimulation of HMC-1 cells by prostaglandins partially contributed to the degranulation. Interestingly, TcdB-treated HMC-1 cells, but not latrunculin B-treated HMC-1 cells, showed a strong p38 MAPK-dependent increase in interleukin-8 release. Differences in the mast cell responses to TcdB and latrunculin B are probably due to the presence of functionally inactive Rho GTPases in toxin-treated cells. Thus, the HMC-1 cell line is a promising model for studying the direct effects of C. difficile toxins on mast cells independently of the tissue context.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517880      PMCID: PMC1951994          DOI: 10.1128/IAI.00195-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

Review 1.  Rho GTPases as therapeutic targets for the treatment of inflammatory diseases.

Authors:  Dezheng Zhao; Charalabos Pothoulakis
Journal:  Expert Opin Ther Targets       Date:  2003-10       Impact factor: 6.902

Review 2.  Rho GTPases and signaling networks.

Authors:  L Van Aelst; C D'Souza-Schorey
Journal:  Genes Dev       Date:  1997-09-15       Impact factor: 11.361

3.  Activated Cdc42/Rac reconstitutes Fcepsilon RI-mediated Ca2+ mobilization and degranulation in mutant RBL mast cells.

Authors:  E Hong-Geller; D Holowka; R P Siraganian; B Baird; R A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

4.  Inhibition of calcium release-activated calcium current by Rac/Cdc42-inactivating clostridial cytotoxins in RBL cells.

Authors:  N Djouder; U Prepens; K Aktories; A Cavalie
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

5.  Effects of toxin A from Clostridium difficile on mast cell activation and survival.

Authors:  G M Calderón; J Torres-López; T J Lin; B Chavez; M Hernández; O Muñoz; A D Befus; J A Enciso
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin.

Authors:  H C Krivan; T D Wilkins
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

7.  Effects of Clostridium difficile toxin B on activation of rat peritoneal mast cells.

Authors:  C B Wex; G Koch; K Aktories
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-03       Impact factor: 3.000

Review 8.  Mast cells as sentinels of innate immunity.

Authors:  S J Galli; M Maurer; C S Lantz
Journal:  Curr Opin Immunol       Date:  1999-02       Impact factor: 7.486

9.  Disruption of the actin cytoskeleton results in nuclear factor-kappaB activation and inflammatory mediator production in cultured human intestinal epithelial cells.

Authors:  Zoltán H Németh; Edwin A Deitch; Marson T Davidson; Csaba Szabó; E Sylvester Vizi; György Haskó
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

10.  Antibiotic-associated diarrhoea and Clostridium difficile in the community.

Authors:  L Beaugerie; A Flahault; F Barbut; P Atlan; V Lalande; P Cousin; M Cadilhac; J-C Petit
Journal:  Aliment Pharmacol Ther       Date:  2003-04-01       Impact factor: 8.171

View more
  26 in total

1.  Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.

Authors:  Hyeun Bum Kim; Quanshun Zhang; Xingmin Sun; Gillian Beamer; Yuankai Wang; Saul Tzipori
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

2.  Clostridium difficile-induced colitis in mice is independent of leukotrienes.

Authors:  Bruno C Trindade; Casey M Theriot; Jhansi L Leslie; Paul E Carlson; Ingrid L Bergin; Marc Peters-Golden; Vincent B Young; David M Aronoff
Journal:  Anaerobe       Date:  2014-09-16       Impact factor: 3.331

Review 3.  Plasticity in mast cell responses during bacterial infections.

Authors:  Cheryl Y Chan; Ashley L St John; Soman N Abraham
Journal:  Curr Opin Microbiol       Date:  2011-11-04       Impact factor: 7.934

4.  Identification of a novel virulence factor in Clostridium difficile that modulates toxin sensitivity of cultured epithelial cells.

Authors:  Masashi Miura; Haru Kato; Osamu Matsushita
Journal:  Infect Immun       Date:  2011-07-11       Impact factor: 3.441

5.  Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B.

Authors:  Ralf Gerhard; Swenja Queisser; Helma Tatge; Gesa Meyer; Oliver Dittrich-Breiholz; Michael Kracht; Hanping Feng; Ingo Just
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-26       Impact factor: 3.000

Review 6.  Clostridium difficile infection in the intensive care unit.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Dis Clin North Am       Date:  2009-09       Impact factor: 5.982

Review 7.  The role of toxins in Clostridium difficile infection.

Authors:  Ramyavardhanee Chandrasekaran; D Borden Lacy
Journal:  FEMS Microbiol Rev       Date:  2017-11-01       Impact factor: 16.408

8.  Systems analysis of the transcriptional response of human ileocecal epithelial cells to Clostridium difficile toxins and effects on cell cycle control.

Authors:  Kevin M D'Auria; Gina M Donato; Mary C Gray; Glynis L Kolling; Cirle A Warren; Lauren M Cave; Michael D Solga; Joanne A Lannigan; Jason A Papin; Erik L Hewlett
Journal:  BMC Syst Biol       Date:  2012-01-06

9.  Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages.

Authors:  Xingmin Sun; Xiangyun He; Saul Tzipori; Ralf Gerhard; Hanping Feng
Journal:  Microb Pathog       Date:  2009-03-24       Impact factor: 3.738

Review 10.  The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.

Authors:  Xingmin Sun; Simon A Hirota
Journal:  Mol Immunol       Date:  2014-09-18       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.